Wednesday, February 10, 2016

Now FDA must act on GSK's Avandia

Food and Drug Administration advisory panel voted 20 to 12 Wednesday to keep GlaxoSmithKline's controversial diabetes drug Avandia on the market in the U.S., albeit recommending with stronger warnings about the increase risk of heart attacks, heart failure and stroke for those taking the medication.

Now FDA must act on GSK’s Avandia

0 comments

A Food and Drug Administration advisory panel voted 20 to 12 Wednesday to keep GlaxoSmithKline’s controversial diabetes drug Avandia on the market in the U.S., albeit recommending with stronger warnings about the increase risk of heart attacks, heart failure and stroke for those taking the medication.

Before the vote on whether or not to take Avandia off the market here, the panel had voted 21 to 4 that the medication increased the risk of heart attacks compared with other medications used to treat diabetes including the competing drug Actos by made by a Japanese pharmaceutical company.

The FDA will now decide on what action if any to take in regards to Avandia. The drug agency is not required to follow the advice of the advisory panel, but usually does. Here's the full story on Wednesday's advisory committee actions.

To check out more Check Up items go to www.philly.com/checkup.

0 comments
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy:

Philly.com comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by Philly.com staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
 
comments powered by Disqus
About this blog

Check Up is a blog for savvy health consumers, covering the latest developments, discoveries, and debates from the Philadelphia area and beyond.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Charlotte Sutton Health and Science Editor, Philadelphia Inquirer
Tom Avril Inquirer Staff Writer, heart health and general science
Stacey Burling Inquirer Staff Writer, neuroscience and aging
Marie McCullough Inquirer Staff Writer, cancer and women's health
Don Sapatkin Inquirer Staff Writer, public health
David Becker, M.D. Board certified cardiologist, Chestnut Hill Temple Cardiology
Michael R. Cohen, R.Ph. President, Institute for Safe Medication Practices
Daniel R. Hoffman, Ph.D. President, Pharmaceutical Business Research Associates
Hooman Noorchashm, M.D., Ph.D. Cardiothoracic surgeon in the Philadelphia area
Amy J. Reed, M.D., Ph.D. Anesthesiologist and Surgical Intensivist in the Philadelphia Area
Latest Health Videos
Also on Philly.com:
letter icon Newsletter